Taysha Gene Therapies, Inc. (TSHA) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	5.5M	9.8M	8.3M	15.5M	2.5M
Cost of Revenue	880.0K	—	—	—	2.5M
Gross Profit	4.6M	9.8M	8.3M	15.5M	15.0K
Operating Expenses
R&D Expense	122.6M	86.4M	66.0M	56.8M	91.2M
SG&A Expense	38.9M	33.9M	29.0M	30.0M	34.9M
General & Admin Expense	38.9M	33.9M	29.0M	30.0M	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(3.7M)	—	4.8M	1.1M	—
Total Operating Expenses	157.8M	120.3M	99.8M	87.9M	126.0M
Cost and Expenses	158.6M	120.3M	99.8M	87.9M	128.5M
Operating Income (EBIT)	(153.2M)	(110.5M)	(91.5M)	(72.4M)	(126.0M)
Non-Operating
Interest Income	10.9M	9.2M	6.9M	3.6M	249.0K
Interest Expense	42.0K	63.0K	102.0K	5.0M	3.8M
Net Interest Income	10.9M	9.2M	6.8M	(1.4M)	(3.5M)
Other Non-Op Income/Expense	3.5M	1.5M	2.2M	(39.1M)	(40.0M)
Non-Operating Income (excl Interest)	(3.0M)	(1.6M)	(2.3M)	34.1M	36.2M
EBT (Pre-Tax Income)	(149.6M)	(109.0M)	(89.3M)	(111.6M)	(166.0M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(149.6M)	(109.0M)	(89.3M)	(111.6M)	(166.0M)
Earnings from Cont. Ops	(149.6M)	(109.0M)	(89.3M)	(111.6M)	(166.0M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(149.6M)	(109.0M)	(89.3M)	(111.6M)	(166.0M)
Per Share
Basic EPS	($0.42)	($0.34)	($0.36)	($0.96)	($3.78)
Diluted EPS	($0.42)	($0.34)	($0.36)	($0.96)	($3.78)
Revenue Per Share	$0.01	$0.03	$0.03	$0.13	$0.06
Shares
Basic Shares Outstanding	369.0M	319.7M	250.1M	116.1M	44.0M
Diluted Shares Outstanding	369.0M	319.7M	250.1M	116.1M	44.0M
Profitability Metrics
EBITDA	(148.8M)	(107.8M)	(88.0M)	(105.2M)	(159.7M)
D&A	1.3M	1.1M	1.2M	1.4M	2.5M
EBIT	(150.1M)	(108.9M)	(89.2M)	(106.6M)	(162.2M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026